Abstract
The binding potential relative to the concentration of nondisplaceable radiotracer in brain (BPND), corresponding to the ratio of the density of neuroreceptors or neurotransporters available to bind radiotracer in vivo (B avail) to the dissociation constant of the radiotracer (K D), can be measured by positron emission tomography (PET) with various radiotracers. PET measures the total radioactivity in brain regions, and therefore the differentiation of specific binding from the background of nondisplaceable binding is a fundamental problem in quantitative analyses of PET data. A true equilibrium condition can be obtained only by continuous intravenous infusion of radiotracer. Equilibrium condition after bolus injection of radiotracer can practically be defined as peak equilibrium at the transient moment when the specific binding is maximal. For equilibrium condition, BPND is expressed as the ratio of radiotracer concentration of specific binding to nondisplaceable binding estimated using a reference region. Kinetic analysis, which is based on the assumption that radiotracer binding can be described by the standard two-tissue compartment model, allows the differentiation of the specific binding from the background of nondisplaceable binding, therefore revealing BPND. For radiotracers with no ideal reference region, BPND can be calculated only by kinetic analysis. Distribution volumes can also be estimated by several graphic plot analyses, as well as by kinetic analysis. Graphic plot analyses can be used to distinguish graphically whether radiotracers show reversible or irreversible binding. A graphic plot analysis recently developed can also be used to distinguish graphically whether the radiotracer binding includes specific binding or not. To avoid the measurement of arterial input function, several quantitative approaches based on the use of a reference region have been developed. Both the simplified reference tissue model and multilinear reference tissue model methods were widely used to calculate BPND without the arterial input function. For each radiotracer and each purpose of PET study, an adequate quantification method should be employed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ito H et al (2008) Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. Neuroimage 39:555–565
Innis RB et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539
Mintun MA et al (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217–227
Huang SC et al (1986) Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. J Cereb Blood Flow Metab 6:515–521
Farde L et al (1989) Kinetic analysis of central [11 C]raclopride binding to D2-dopamine receptors studied by PET-a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696–708
Ito H et al (1998) Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11 C]raclopride binding. J Cereb Blood Flow Metab 18:941–950
Lassen NA (1992) Neuroreceptor quantitation in vivo by the steady-state principle using constant infusion or bolus injection of radioactive tracers. J Cereb Blood Flow Metab 12:709–716
Carson RE et al (1993) Comparison of bolus and infusion methods for receptor quantitation: application to [18 F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24–42
Laruelle M et al (1994) SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: I. Kinetic modeling of single bolus experiments. J Cereb Blood Flow Metab 14:439–452
Ikoma Y et al (2007) Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [11 C]DAA1106. J Cereb Blood Flow Metab 27:173–184
Logan J et al (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11 C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740–747
Logan J et al (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834–840
Koeppe RA et al (1991) Compartmental analysis of [11 C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735–744
Ito H et al (1996) A simple method for the quantification of benzodiazepine receptors using iodine-123 iomazenil and single-photon emission tomography. Eur J Nucl Med 23:782–791
Ito H et al (2010) A new graphic plot analysis for determination of neuroreceptor binding in positron emission tomography studies. Neuroimage 49:578–586
Yokoi T et al (1993) A new graphic plot analysis for cerebral blood flow and partition coefficient with iodine-123-iodoamphetamine and dynamic SPECT validation studies using oxygen-15-water and PET. J Nucl Med 34:498–505
Lammertsma AA et al (1996) Comparison of methods for analysis of clinical [11 C]raclopride studies. J Cereb Blood Flow Metab 16:42–52
Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158
Gunn RN et al (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6:279–287
Cselenyi Z et al (2006) A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11 C]FLB 457 and [11 C]WAY 100635. Neuroimage 32:1690–1708
Ichise M et al (1996) Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med 37:513–520
Ichise M et al (2003) Linearized reference tissue parametric imaging methods: application to [11 C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096–1112
Farde L et al (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatr 45:71–76
Suhara T et al (2003) High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatr 60:386–391
Ito H et al (2009) No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. Int J Neuropsychopharmacol 12:667–675
Endres CJ et al (1997) Kinetic modeling of [11 C]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab 17:932–942
Acknowledgments
The assistance of members of the National Institute of Radiological Sciences staff in performing the PET experiments is gratefully acknowledged.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this protocol
Cite this protocol
Ito, H., Naganawa, M., Seki, C., Takano, H., Kanno, I., Suhara, T. (2012). Quantification of Neuroreceptors and Neurotransporters. In: Gründer, G. (eds) Molecular Imaging in the Clinical Neurosciences. Neuromethods, vol 71. Humana Press, Totowa, NJ. https://doi.org/10.1007/7657_2012_44
Download citation
DOI: https://doi.org/10.1007/7657_2012_44
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-988-4
Online ISBN: 978-1-61779-989-1
eBook Packages: Springer Protocols